Health Technology · Pharmaceuticals: Major · NSE: KOPRAN · data 2026-10-09
Kopran Limited
Health check: Average (5.4/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹251.05
Market cap
₹1,227 cr
P/E
48.5
P/B
—
ROE
4.9%
ROCE
10.1%
Debt / equity
0.29
Dividend yield
1.18%
1-year return
45.3%
52-week high
₹295.83
52-week low
₹107
Operating margin
8.7%
Growth
| Revenue (last 12 months) | ₹700 cr |
| Net profit (last 12 months) | ₹25 cr |
| Sales growth, 3 years (yearly) | 7.2% |
| Profit growth, 3 years (yearly) | -1.9% |
Similar companies
Bharat Parenterals Ltd. (BPLPHARMA) · Remus Pharmaceuticals Ltd. (REMUS) · Lincoln Pharmaceuticals Ltd (LINCOLN) · Sigachi Industries Limited (SIGACHI) · Bajaj Healthcare Ltd (BAJAJHCARE)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open KOPRAN in NSE Scanner →